By Fineline Cube 
Siemens Healthineers AG (ETR: SHL), a Germany-based medical device giant is reportedly in exploratory talks to sell its diagnostics division to one or more of the world’s biggest private‑equity firms. Bloomberg sourced the information from industry insiders familiar with the discussions.
Potential Buyers
- Blackstone Inc. – One of the largest U.S. private‑equity funds.
- CVC Capital Partners Plc – A leading European private‑equity player.
- KKR & Co. – Global investment firm with a history of acquiring health‑tech assets.
- Montagu – Another private‑equity group that has shown prior interest.
These firms have reportedly held preliminary conversations with Siemens Healthineers, though no formal offers have been disclosed.
Deal Valuation
- Estimated Value: €6 billion (≈ USD 7 billion).
- Scope: The sale would encompass the entire diagnostics unit, including imaging, pathology, and laboratory services.
Advisors may be retained if the dialogue moves beyond the exploratory phase, but nothing has been formally structured yet.
Current Status
- Uncertainty: No certainty that the early discussions will culminate in a transaction.
- Company Position: Siemens Healthineers could decide to retain the diagnostics business, maintaining its integrated health‑care portfolio.
Representatives from Siemens Healthineers and the interested private‑equity firms declined to comment on the matter.
Implications for the Health‑Tech Market
- Strategic Realignment: A sale could allow Siemens Healthineers to concentrate on core revenue streams such as imaging and life‑sciences.
- Private‑Equity Momentum: The interest from Blackstone, CVC, and KKR underscores the growing appetite for high‑growth, technology‑heavy health‑care assets.
- Valuation Benchmark: A €6 billion valuation would set a new precedent for diagnostics units within large, diversified medical‑equipment groups.
Investors and analysts will watch for any formal announcement as the negotiation window widens in the coming months.-Fineline Info & Tech